Saturday 17 October 2026
Export BTMD’s income statement to Excel — free account
biote Corp.
BTMD Healthcare Medical Care Facilities
biote Corp.’s revenue for fiscal 2025 (year ended December 2025) was $192.2 million, down 2.52% from fiscal 2024. In the quarter to June 2026, revenue fell 9.48%, EPS fell 330.0%, free cash flow fell 174.2% and total debt rose 16.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.09
0.02
−1.80%
Follow BTMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.81 | 2.76 | 3.02 | 3.26 |
+8 more quarters Free account |
P/S ratio |
0.29 | 0.22 | 0.42 | 0.48 | |
P/FCF ratio |
3.09 | 1.56 | 2.87 | 2.73 | |
P/Operating CF |
(46.01) | 10.60 | 10.75 | 6.68 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.90 | 0.75 | 0.85 | 0.87 | |
EV/EBITDA |
8.48 | 4.21 | 4.10 | 4.68 | |
EV/Operating CF |
6.75 | 4.34 | 4.67 | 4.23 | |
EV/FCF |
9.39 | 5.36 | 5.80 | 4.92 | |
Quick Ratio |
0.63 | 0.45 | 0.69 | 0.64 | |
Current Ratio |
1.43 | 1.29 | 1.22 | 1.01 | |
Net Debt/EBITDA |
(46.50) | 23.06 | 10.37 | 7.99 | |
Debt/Assets |
119.47% | 118.69% | 99.46% | 92.86% | |
Debt/Equity |
(2.09) | (2.20) | (2.12) | (1.58) | |
Asset Turnover |
1.78 | 1.77 | 1.67 | 1.84 | |
Operating CF/Net income |
0.18 | 1.71 | 3.87 | 1.72 | |
Capex/Depreciation |
(2.31) | (0.98) | (2.03) | (0.60) | |
Interest Coverage |
(1.61) | 1.61 | 2.76 | 3.02 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
73.31% | 61.84% | 53.32% | 54.53% | |
Intangible Assets out of Total Assets |
0.09 | 0.11 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
4.45% | 3.91% | 4.74% | 5.03% | |
Graham Net Nets |
(2.16) | (2.43) | (1.27) | (1.27) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
8.47% | 36.30% | 33.08% | 30.67% | |
Free Cash Flow Yield |
32.38% | 63.92% | 34.83% | 36.61% | |
Revenue per Share |
1.55 | 1.47 | 1.48 | 1.53 | |
Operating CF per Share |
(0.04) | 0.13 | 0.24 | 0.45 | |
Capex per Share |
(0.09) | (0.04) | (0.08) | (0.02) | |
Free Cash Flow per Share |
(0.13) | 0.09 | 0.17 | 0.43 | |
Cash per Share |
0.39 | 0.17 | 0.77 | 0.90 | |
Shareholders Equity per Share |
(2.03) | (1.56) | (1.61) | (2.09) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.03) | (1.56) | (1.61) | (2.09) | |
Free Cash Flow |
(3.80) | 2.73 | 5.21 | 13.38 | |
Working Capital |
12.94 | 8.13 | 9.68 | 0.82 | |
Capital Expenditures |
(2.62) | (1.17) | (2.36) | (0.69) | |
Net Current Asset Value |
(116.85) | (100.63) | (103.34) | (119.67) | |
EV/EBIT |
11.15 | 4.88 | 4.62 | 5.38 | |
Capex to Sales |
0.06 | 0.03 | 0.05 | 0.01 | |
Price to Operating Income |
3.67 | 1.43 | 2.29 | 2.99 | |
| Other line items | |||||
Average Receivables |
8.44 | 7.58 | 7.25 | 8.23 | |
Average Payables |
5.22 | 5.79 | 6.32 | 4.37 | |
Average Inventory |
15.23 | 16.67 | 16.95 | 16.32 | |
Average Assets |
103.25 | 106.21 | 114.99 | 106.29 | |
Average Common Equity |
(68.52) | (66.39) | (76.30) | (96.15) |
Columns are period end dates